Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + trastuzumab
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pembrolizumab + trastuzumab is a combination of two monoclonal antibodies used in oncology. Pembrolizumab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD‑1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby enhancing anti-tumor immune responses. Trastuzumab is a recombinant humanized IgG1 monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways involved in cell proliferation and survival, and mediating antibody-dependent cellular cytotoxicity. This combination has been approved for use with chemotherapy as first-line treatment for adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1)[3][9][4]. The regimen leverages both targeted therapy against HER2 and immune checkpoint inhibition.
- Other names
- pembrolizumab + trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + trastuzumab.